Janux Therapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGJanux Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 40), showing significant lag compared to the market leaders. Earnings contraction of 3% provides fundamental context to the price action. Investors should exercise caution due to high volatility (74% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $14.01 | +6.63% | ABOVE |
| 50 SMA | $14.38 | +3.89% | ABOVE |
| 100 SMA | $14.10 | +5.93% | ABOVE |
| 150 SMA | $15.16 | -1.44% | BELOW |
| 200 SMA | $17.82 | -16.15% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is JANX in an uptrend right now?
JANX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is JANX overbought or oversold?
JANX's RSI (14) is 57. The stock is in neutral territory, neither overbought nor oversold.
Is JANX outperforming the market?
JANX has a Relative Strength (RS) Rating of 40 out of 99. JANX is currently lagging the broader market.
Where is JANX in its 52-week range?
JANX is trading at $14.94, which is 42% of its 52-week high ($35.34) and 12% above its 52-week low ($12.12).
How volatile is JANX?
JANX has a Beta of 1.32 and 52-week volatility of 74%. It's more volatile than the S&P 500 - expect bigger swings.